Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Clinical Genitourinary Cancer|October 1, 2008
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer, Bryan Goldman, Timothy W Synold, et al.
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
Tomography (Ann Arbor, Mich.)|January 10, 2017
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance ImagingWei Huang, Brooke R Beckett, Alina Tudorica, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Cancer|April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohortSandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Cell Reports. Medicine|June 7, 2021
Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinomaHui-Wen Lue, Daniel S Derrick, Soumya Rao, et al.
Clinical Genitourinary Cancer|December 3, 2014
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancerKevin D Courtney, Judith B Manola, Aymen A Elfiky, et al.
Cancer|February 15, 2024
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancerSandip P Patel, Elizabeth Guadarrama, Young Kwang Chae, et al.
Magnetic Resonance Imaging|August 18, 2012
Promise and pitfalls of quantitative imaging in oncology clinical trialsBrenda F Kurland, Elizabeth R Gerstner, James M Mountz, et al.
Pageof 15